Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differences

Journal of Structural Biology

Volumn 171, Issue 1, 2010, Pages 95-101

  Dewilde, Maarten ^a   Van De Craen, Britt ^a   Compernolle, Griet ^a   Madsen, Jeppe B ^a   Strelkov, Sergei ^b   Gils, Ann ^a   Declerck, Paul J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

Crystal structure; PAI 1; Plasminogen activator inhibitor 1; Rational drug design; Serpin

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ALPHA HELIX; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG DESIGN; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; MOUSE; NONHUMAN; ORTHOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SEQUENCE ALIGNMENT; STRUCTURE ANALYSIS;

ANIMALS; BINDING SITES; CRYSTALLIZATION; HUMANS; MICE; MODELS, MOLECULAR; MUTATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, PROTEIN; SERPIN E2;

ANIMALIA; RATTUS;

EID: 77953615441     PISSN: 10478477     EISSN: 10958657     Source Type: Journal    
DOI: 10.1016/j.jsb.2010.03.006     Document Type: Article

References (44)

1. Aertgeerts K., De Bondt H.L., De Ranter C.J., Declerck P.J. Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1. Nat. Struct. Biol. 1995, 2:891-897.
2. Bajou K., Noel A., Gerard R.D., Masson V., Brunner N., Holst-Hansen C., Skobe M., Fusenig N.E., Carmeliet P., Collen D., Foidart J.M. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 1998, 4:923-928.
3. Berkenpas M.B., Lawrence D.A., Ginsburg D. Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J. 1995, 14:2969-2977.
4. Binder B.R., Mihaly J. The plasminogen activator inhibitor " paradox" in cancer. Immunol. Lett. 2008, 118:116-124.
5. Cale J.M., Li S.H., Warnock M., Su E.J., North P.R., Sanders K.L., Puscau M.M., Emal C.D., Lawrence D.A. Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1. J. Biol. Chem. 2010, 285:7892-7902.
6. Carmeliet P., Stassen J.M., Schoonjans L., Ream B., van den Oord J.J., De Mol M., Mulligan R.C., Collen D. Plasminogen activator inhibitor-1 gene deficient mice. II. Effects on hemostasis, thrombosis and thrombolysis. J. Clin. Invest. 1993, 92:2756-2760.
7. Davis I.W., Leaver-Fay A., Chen V.B., Block J.N., Kapral G.J., Wang X., Murray L.W., Arendall W.B., Snoeyink J., Richardson J.S., Richardson D.C. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 2007, 35:W375-W383.
8. Declerck P.J., De Mol M., Alessi M.C., Baudner S., Paques E.P., Preissner K.T., Muller Berghaus G., Collen D. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J. Biol. Chem. 1988, 263:15454-15461.
9. Declerck P.J., De Mol M., Vaughan D.E., Collen D. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator. J. Biol. Chem. 1992, 267:11693-11696.
10. Dementiev A., Dobo J., Gettins P.G. Active site distortion is sufficient for proteinase inhibition by serpins: structure of the covalent complex of alpha1-proteinase inhibitor with porcine pancreatic elastase. J. Biol. Chem. 2006, 281:3452-3457.
11. Dewilde M., Strelkov S.V., Rabijns A., Declerck P.J. High quality structure of cleaved PAI-1-stab. J. Struct. Biol. 2009, 165:126-132.
12. Durand M.K., Bodker J.S., Christensen A., Dupont D.M., Hansen M., Jensen J.K., Kjelgaard S., Mathiasen L., Pedersen K.E., Skeldal S., Wind T., Andreasen P.A. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb. Haemost. 2004, 91:438-449.
13. Egelund R., Rodenburg K.W., Andreasen P.A., Rasmussen M.S., Guldberg R.E., Petersen T.E. An ester bond linking a fragment of a serine proteinase to its serpin inhibitor. Biochemistry 1998, 37:6375-6379.
14. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D. Biol. Crystallogr. 2004, 60:2126-2132.
15. Engh R.A., Schulze A.J., Huber R., Bode W. Serpin structures. Behring Inst. Mitt. 1993, 93:41-62.
16. Erickson J., Neidhart D.J., VanDrie J., Kempf D.J., Wang X.C., Norbeck D.W., Plattner J.J., Rittenhouse J.W., Turon M., Wideburg N. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science 1990, 249:527-533.
17. Gils A., Declerck P.J. Proteinase specificity and functional diversity in point mutants of plasminogen activator inhibitor 1. J. Biol. Chem. 1997, 272:12662-12666.
18. Gils A., Knockaert I., Declerck P.J. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. Biochemistry 1996, 35:7474-7481.
19. Gils A., Meissenheimer L.M., Compernolle G., Declerck P.J. Species-dependent molecular drug targets in plasminogen activator inhibitor-1 (PAI-1). Thromb. Haemost. 2009, 102:609-610.
20. Hekman C.M., Loskutoff D.J. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J. Biol. Chem. 1985, 260:11581-11587.
21. Huntington J.A., Read R.J., Carrell R.W. Structure of a serpin-protease complex shows inhibition by deformation. Nature 2000, 407:923-926.
22. Jensen J.K., Gettins P.G. High-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling. Protein Sci. 2008, 17:1844-1849.
23. Juhan-Vague I., Alessi M.C., Declerck P.J. Pathophysiology of fibrinolysis. Baillieres Clin. Haematol. 1995, 8:329-343.
24. Kabsch W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Crystallogr. 1993, 26:795-800.
25. Kruithof E.K., Tran Thang C., Ransijn A., Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984, 64:907-913.
26. Lijnen H.R. Pleiotropic functions of plasminogen activator inhibitor-1. J. Thromb. Haemost. 2005, 3:35-45.
27. McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., Read R.J. Phaser crystallographic software. J. Appl. Crystallogr. 2007, 40:658-674.
28. Mestas J., Hughes C.C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 2004, 172:2731-2738.
29. Mottonen J., Strand A., Symersky J., Sweet R.M., Danley D.E., Geoghegan K.F., Gerard R.D., Goldsmith E.J. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992, 355:270-273.
30. Munch M., Heegaard C.W., Andreasen P.A. Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor. Biochim. Biophys. Acta 1993, 1202:29-37.
31. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D. Biol. Crystallogr. 1997, 53:240-255.
32. Nar H., Bauer M., Stassen J.M., Lang D., Gils A., Declerck P.J. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. J. Mol. Biol. 2000, 297:683-695.
33. Narayanaswamy M., Wright K.C., Kandarpa K. Animal models for atherosclerosis, restenosis, and endovascular graft research. J. Vasc. Interv. Radiol. 2000, 11:5-17.
34. Ngo T.H., Zhou Y., Stassen J.M., Declerck P.J. Importance of N-terminal residues in plasminogen activator inhibitor 1 on its antibody induced latency transition. Thromb. Haemost. 2002, 88:288-293.
35. Prins M.H., Hirsh J. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Arch. Intern. Med. 1991, 151:1721-1731.
36. Sharp A.M., Stein P.E., Pannu N.S., Carrell R.W., Berkenpas M.B., Ginsburg D., Lawrence D.A., Read R.J. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Struct. Fold. Des. 1999, 7:111-118.
37. Shore J.D., Day D.E., Francis Chmura A.M., Verhamme I., Kvassman J., Lawrence D.A., Ginsburg D. A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism. J. Biol. Chem. 1995, 270:5395-5398.
38. Stein, P.E., Baek, K., 2002. 1.8Å resolution structure of latent plasminogen activator inhibitor-1. Protein data bank code 11j5. Ref Type: Unpublished Work.
39. Stout T.J., Graham H., Buckley D.I., Matthews D.J. Structures of active and latent PAI-1: a possible stabilizing role for chloride ions. Biochemistry 2000, 39:8460-8469.
40. van Meijer M., Pannekoek H. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update. Fibrinolysis 1995, 9:261-276.
41. Wiman B. Predictive value of fibrinolytic factors in coronary heart disease. Scand. J. Clin. Lab. Invest. 1999, 59:23-31.
42. Xu Z., Balsara R.D., Gorlatova N.V., Lawrence D.A., Castellino F.J., Ploplis V.A. Conservation of critical functional domains in murine plasminogen activator inhibitor-1. J. Biol. Chem. 2004, 279:17914-17920.
43. Xue Y., Björquist P., Inghardt T., Linschoten M., Musil D., Sjölin L., Deinum J. Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide. Structure 1998, 6:627-636.
44. Zhou A., Huntington J.A., Pannu N.S., Carrell R.W., Read R.J. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat. Struct. Biol. 2003, 10:541-544.